fbpx
Medical Innovation Exchange

Not an 'excellent outcome' for Athersys stock as stem cell therapy misses endpoint in Japanese trial

https://www.fiercebiotech.com/biotech/athersys-stock-plunges-60-wake-stroke-stem-cell-therapy-missing-endpoint

Leave a Comment

Your email address will not be published.

Leave the field below empty!

This site uses Akismet to reduce spam. Learn how your comment data is processed.